LT3001 China region out-Licensed to Shanghai Pharma

Lumosa Therapeutics Co., Ltd. (“Lumosa;” 6535.TWO) announced the successful licensing deal on its LT3001, a novel drug for the treatment of acute ischemic stroke (“Product”), in the China region with Shanghai Pharmaceutical Group Co., Ltd. (“Shanghai Pharma, SHP;” 601607.SS; 02607.HK), one of the top-tier publicly-traded pharmaceutical companies in China. Both companies will collaborate to enter the global market through the sharing of clinical trial data.

Naldebain to enter Switzerland

Lumosa Enters Exclusive Distribution Agreement for Its Extended-Release Analgesic Injection with Swiss’s Ideogen AG

Lumosa to launch the Phase 2 Study for its LT3001

Lumosa to Initiate Phase 2 Human Clinical Trial in the US and Taiwan for Its LT3001, A Novel Drug for the Treatment of Acute Ischemic Stroke

LT3001 patent granted in Japan and Mexico

Lumosa Therapeutics (Lumosa; code:6535.TWO), a new drug development company in Taiwan, announces that the compound patent of its LT3001, a new drug currently under development for the treatment of acute ischemic stroke (AIS), has been granted by the Japan Patent Office and Mexican Institute of Industrial Property. These are additional patents issued in major markets after the issuance of the United States and China patents. Lumosa’s LT3001 compound patent has been granted in 8 countries so far, including China, the US, Australia, Russia, Taiwan, Indonesia, Japan and Mexico. A total of ten patent applications in other jurisdictions are under examination. 

Formulation patent for Naldebain approved

New U.S. Patent Granted to Lumosa for Naldebain(R), a Long-acting Analgesic for Moderate to Severe Post-Operative Pain

Lumosa partner submitted clinical trial application for LT1001 in China

Lumosa Therapeutics Co., Ltd. (6535. TWO) (“Lumosa”) today announced that its partner, Syntano Technology Venture (“Syntano”), a subsidiary of the Haike group, has submitted Clinical Trial Application (CTA) to the China National Drug Administration (CNDA) for Lumosa’s long-acting analgesic injection, LT1001 (the product name used in Taiwan: Naldebain®) as a Class 5.1 New Drug. Lumosa will receive milestone payment correspondingly. Clinical trials for Class 5.1 (Imported New Drugs) require fewer subjects for confirmatory purpose, which would shorten the registration process for LT1001 to be launched in China.